Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Jurjen Krommenhoek et al., published in RPTH Journal, adding:
“Does reversing factor Xa inhibitors really carry as much thrombotic risk as we think?
Real-world data from the Netherlands offer a reassuring perspective.
Among 217 patients treated with andexanet alfa, the 30-day thrombotic event rate was just 4.6%, substantially lower than reported in major clinical trials.
Even more striking, no thrombotic events occurred after anticoagulation was restarted, reinforcing the importance of timely reinitiation when clinically appropriate.
A valuable real-world look at balancing life-saving bleeding reversal with thrombotic risk.”
Title: Andexanet alfa for the reversal of anticoagulation: Dutch practice data
Authors: Jurjen F Krommenhoek, Wendy Beekman, Flip Kor, Pim Gal, Willemijn E M Berkhout, Karina Meijer, Dionne C W Braeken, Frederikus A Klok, Hugo ten Cate, Renske H Olie
Other articles featuring RPTH Journal on Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda